Rituximab Biosimilar (LALAPG) - Research Grade

Rituximab Biosimilar (LALAPG) - Research Grade, Host: CHO Cells, Human IgG1 (LALAPG)-Kappa

Target: CD20

Specificity: Detects human CD20. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Rituximab.

Purification method: This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Background: Rituximab is a genetically engineered chimeric murine/human monoclonal IgG1 kappa antibody directed against the CD20 antigen. Rituximab has an approximate molecular weight of 145 kD. Rituximab is produced by mammalian cell (Chinese Hamster Ovary).

Concentration: 1.0 - 5.0 mg/ml

Formulation: Phosphate buffered saline (PBS) pH 7.2,with no carrier protein, potassium or preservatives added. BSA and Azide free.

Purity: >95% by SDS-PAGE and HPLC

Endotoxin: ≤ 1.0 EU/mg as determined by the LAL method

Use: Products are for research use only. Not for use in diagnostic or therapeutic procedures.

• Artikelnummer: ICH4011LALAPG-100mg
• Hersteller: Ichorbio
• Hersteller Artikelnummer: ICH4011LALAPG-100mg
• Verpackungseinheit: 100mg
• Mengeneinheit: STK
• Reaktivität: Human
• Klonalität: Monoclonal
• Isotyp: Human IgG1 (LALAPG)-Kappa
• Wirt: Cell Line